31 Jul 06

Atrial fibrillation (AF) is the most common form of arrhythmia, or irregular heartbeat, with an estimated nine million sufferers worldwide. Although safe, effective treatment for AF is critical, historically there has been little R&D investment and little innovation in the AF market. However, this may be about to change, with the AF market expected to triple by 2015.
Datamonitor

25 Jul 06

Cognitive behaviour therapy (CBT) combines two very effective kinds of psychotherapy delivered face to face by medical therapists
Jim Melling - PharmiWeb Field Reporter

25 Jul 06

In the last report we analysed part of an SOP control system for inefficiencies and opportunities for error, by mapping the system and asking ‘what if?’ at each stage. But, as we mentioned previously, documentation systems (or, indeed, any type of control system) rarely operate in isolation. So let’s look at some of the inputs and outputs there might be on a typical site, using the same process as before.
Joanna Hills - PharmiWeb Field Reporter

25 Jul 06

A well-run documentation system will support your business processes and improvements, not hold them back. How do you ensure that this is the case?
Joanna Hills - PharmiWeb Field Reporter

21 Jul 06

PowderMed has submitted an application to UK regulators seeking to conduct human trials of its avian influenza vaccine. Developing an effective vaccine against the next influenza pandemic is a challenging task, but one many companies are taking on. However, until a virus able to cause a pandemic emerges, no one knows for certain which product will be most effective.
Datamonitor

19 Jul 06

Hints and Tips: Survive in the Work Place Part Two
Elaine Ford - PharmiWeb Field Reporter

13 Jul 06

'Drug In Focus' is written by Leighton Howard, a patent information expert with extensive generics experience. He has worked within the professional patent information industry and major generic pharmaceutical firms and now provides consultancy services to the generics industry and government organisations via his company XIP Pty Ltd. He is also the founder of GenericsWeb and remains instrumental in maintaining the high quality and accuracy of data contained in Pipeline Patent Intelligence.
Leighton Howard

11 Jul 06

Hints and tips to survive in the work place
Elaine Ford - PharmiWeb Field Reporter

11 Jul 06

Hints and tips for job hunting
Elaine Ford - PharmiWeb Field Reporter

11 Jul 06

A new class of drug for tophaceous gout, the first to be developed in 40 years, is generating hope for patients currently unable to tolerate or respond to standard therapies.
Olwen Glynn Owen - PharmiWeb Field Reporter

11 Jul 06

Baraclude (entecavir), a new oral drug developed by Bristol-Myers Squibb, recently approved by the European Commission for treatment of chronic hepatitis B viral (HBV) infections, is expected to become available in a few months in some countries of the EU, the Middle East and Africa.
Olwen Glynn Owen - PharmiWeb Field Reporter

09 Jul 06

Pharmaceutical companies are renowned for exhaustive pages of regulatory reports and documentation procedures. An enormous amount of effort goes into creating and maintaining these documentations, usually by people for whom it is only a small part of their job. Another problem is that complexity exists in such documents and may be due to an excess of information or to inappropriate structure. Again, historically there may have been a drive to put every little detail into the procedures, in t
PharmiWeb Field Reporter -Joanna Hills

05 Jul 06

A recent Department of Health study showed that healthcare associated infection (HCAI) affects 8 per cent of acute admissions to hospitals. These infections can delay discharge home by up to 11 days. For the NHS in England this represents a loss of 3.6 million bed days, with a projected cost of £1 billion a year.
Maureen Bott, Kalamazoo Security Print

14 Jun 06

Data presented at the American Society of Clinical Oncology (ASCO) meeting in Atlanta this month suggest that administering the epidermal growth factor receptor (EGFR) inhibitor Erbitux (cetuximab) fortnightly rather than weekly in metastatic colorectal cancer (mCRC) is a feasible option. Another study probing whether scaling up the dose, to the point where patients experience the significant rash linked to long survival, achieves a better response, shows high doses are well tolerated.
Olwen Glynn Owen - PharmiWeb Field Reporter

08 Jun 06

DailyUpdates 2nd June: In today’s edition of DailyUpdates we highlight exciting new data on the potential use of the antihypertensive, losartan as a modulator of insulin release and production and hence a directly acting therapeutic for the treatment of diabetes. This supplements additional beneficial activity resulting from blood pressure control. In addition we report on European approval of Thelin, Encysive’s candidate for the treatment of pulmonary hypertension
LeadDiscovery

31 May 06

DailyUpdates 26th May, 2006: As our daily trip around the drug discovery world continues we hit Friday with some revealing information on sepsis and new phase 3 data on Wyeth's antidepressant desvenlafaxine. Read on for more about these highlight on visit today's edition of DailyUpdates for more on these advances or any of the other 50+ items featured today
LeadDiscovery

31 May 06

EntreMed has initiated a phase II trial of Panzem in combination with Genentech's Avastin in carcinoid cancer. The trial will examine how the therapy fares against potential rivals and its possible use in other tumor types. With the blockbuster Avastin possessing the potential to significantly raise the profile of Panzem, the study will prove crucial for EntreMed's lead pipeline drug candidate.
Datamonitor

23 May 06

Colin Williams, e-Marketing Director at PharmiWeb Solutions takes a look at the current e-detailing landscape and suggests what the future could hold for this much talked about tool for pharmaceutical sales and marketing departments.
Colin Williams

19 May 06

Without treatment, an estimated one in three women will experience an osteoporosis-related fracture during their lifetime
Olwen Glynn Owen

17 May 06

Despite almost 200 million people suffering from hypertension in the seven major pharmaceutical markets alone, according to a new report, innovation is scarce within antihypertensive R&D. What little innovation that does exist is being delivered by Novartis, which is set to launch two new antihypertensives in 2007 in the shape of oral renin inhibitor Rasilez, and the 'two-in-one' pill Exforge.
Datamonitor

17 May 06

EntreMed has initiated a phase II trial of Panzem in combination with Genentech's Avastin in carcinoid cancer. The trial will examine how the therapy fares against potential rivals and its possible use in other tumor types. With the blockbuster Avastin possessing the potential to significantly raise the profile of Panzem, the study will prove crucial for EntreMed's lead pipeline drug candidate.
Datamonitor

15 May 06

DailyUpdates 15th May, 2006: Amongst the 50 or so papers and press releases featured today two focusing on VEGF jump out as being of especial interest. The first, a paper published by Stanford University, reports on the anti-cancer activity of an oncolytic virus in combination with gene therapy. The virus was engineered to selectively replicate in and kill cancer cells . The gene therapy encoded a soluble version of Flk1, one of the VEGF receptors. The two approaches together produce effective a
LeadDiscovery

13 May 06

This summit aims to provide both strategic and practical information that will ensure that organisations can prepare for and survive what is now considered to be the inevitable pandemic. Professor Hugh Pennington from the Department of Medical Microbiology at University of Aberdeen will repeat his warning that, “Only one thing is certain and that is that there will be a pandemic.”
Susie Wilson

12 May 06

DailyUpdates 12th May, 2006 (click here for entire bulletin): Today appears to be cancer vaccine day with two important announements being made. First off, Genitope Corporation announce the initiation of an ealry phase clinical trial of their MyVax idiotype immunotherapy; this was followed by an announcement by Biovest reporting that fast track status had been awarded to their phase 3 candidate, BiovaxID. This follows in the footsteps of the company's announcement that the FDA had approved sale
LeadDiscovery

11 May 06

A new report estimates that there will be approximately 84,000 cases of adult and childhood leukemia in the world's seven major pharmaceutical markets in 2006. Acute leukemias will account for 43% of these cases, and, although this market is relatively small compared to other cancer types, the clear unmet needs and regulatory incentives should help encourage drug makers.
Datamonitor

05 May 06

In recent years, parallel trade of pharmaceutical products has grown to some the highest levels ever seen, exerting additional pressure on pharmaceutical companies' profitability. Companies need to be proactive to restrict parallel trade, especially in the EU, which is expected to continue to be the market of most concern for pharmaceutical firms.
Datamonitor

27 Apr 06

In many areas there is a long waiting list for CBT delivered by a therapist and these new programmes offer genuine help for patients, which ought to reduce waiting lists and give greater access to services.
Jim Melling

27 Apr 06

Travellers’ Diarrhoea (TD) frequently occurs in individuals from industrialised countries when visiting destinations in developing countries. Consequences of TD include disruption of holiday and work capacity, and occasionally severe chronic disease. Existing methods of prevention are inadequate. We calculate that the number of travellers to TD risk regions was 88 million in 2003 and may reach 190 million per annum by 2020, suggesting that a significant potential market exists for a TD vaccine.
Nicholas Miller and Ingelise Saunders

25 Apr 06

Specialty Pharma transformations and venture investments have continued to grow at an unprecedented pace. The 2006 meeting is an elite opportunity for Big Pharma, Biotech, and Drug Delivery to network with the industry's fastest growing Specialty Pharma companies and discover what makes them so attractive as a partner.
Ed Drilon

25 Apr 06

The Definitive Conference for Clinical Research Contract Professionals!
Glenn Pascual